DealCelea Therapeutics, a Boston-based lung disease therapeutics developer, raised $180 million in a financing round led by RA Capital Management and Leaps by Bayer with participation from PureTech Health.
More on MedCity News →
OTHER
07/10/2026
Respiro Diagnostics, a Leeds, United Kingdom-based breath-based lung...
Pediatrica Health Group, a Boston-based pediatric primary care network,...
Iswarya, a Chennai-based fertility care provider, raised ₹3.5 billion in...
Myricx Bio, a London-based ADC payload platform biotech, was acquired for...
Stepful, a New York-based healthcare workforce training platform, raised...
Pearl Health, a New York-based value-based care platform, raised $110...
Stay informed on industry shifts, deal trends, and career opportunities in venture capital.
